Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Physiol Behav ; 272: 114351, 2023 Dec 01.
Article in English | MEDLINE | ID: mdl-37714321

ABSTRACT

Epilepsy is the most common neurological disorder which is accompanied with behavioral and psychiatric alternations. Current evidences have shown that (-)-α-bisabolol (BSB) possess anti-inflammatory and antioxidative effects in several animal studies. Here, we conducted present study to evaluate its neuroprotective effects against pentylenetetrazole (PTZ)-induced seizures in rats. We used fifty male rats and they were randomly assigned into 5 groups control, BSB100, PTZ, BSB50 + PTZ, BSB100 + PTZ. The animals intraperitoneally received PTZ (45 mg/kg) for ten consecutive days to induce epilepsy model. BSB in doses of 50 and 100 mg/kg was administrated orally one hour before PTZ administration for ten days. The elevated plus maze (EPM) test was carried out to assess anxiety-like behavior. The seizure intensity was evaluated according to modifies Racine's convulsion scale (RCS). Y-maze and passive avoidance were utilized to assess working memory and aversive memory. The expression of pro-inflammatory cytokines and oxidative stress factors were measured using the enzyme-linked immunosorbent assay (ELISA). The neuronal cell loss in the hilar region was assessed using Nissl staining. Results showed that PTZ-treated rats had more seizure intensity, anxiety-like behavior, memory deficits, higher levels of TNF-α, IL-1ß, and oxidative markers. Pre-treatment with BSB 100 significantly inhibited seizure intensity, anxiety-like behavior, and memory deficits; reduced levels of TNF-α, IL-1ß, and MDA oxidative markers. Collectively, outcome of this work shows that BSB at the dose of 100 mg/kg may exert neuroprotective effects by mitigating seizures, oxidative stress, and neuroinflammation, and ameliorates memory and anxiety disorders in the PTZ-induced seizure rats.


Subject(s)
Epilepsy , Neuroprotective Agents , Rats , Male , Animals , Pentylenetetrazole/toxicity , Neuroprotective Agents/pharmacology , Neuroprotective Agents/therapeutic use , Tumor Necrosis Factor-alpha/metabolism , Rats, Wistar , Seizures/chemically induced , Seizures/drug therapy , Seizures/metabolism , Oxidative Stress , Memory Disorders/drug therapy , Inflammation/chemically induced , Inflammation/drug therapy , Anticonvulsants/pharmacology , Anticonvulsants/therapeutic use , Disease Models, Animal
SELECTION OF CITATIONS
SEARCH DETAIL
...